Alzheimer’s disease: the potential of epigenetic treatments and current clinical candidates

Alzheimer’s disease is a progressive and fatal neurodegenerative disease affecting 50 million people worldwide, characterized by memory loss and neuronal degeneration. Current treatments have limited efficacy and there is no cure. Alzheimer's is likely caused by a combination of factors, provid...

Full description

Saved in:
Bibliographic Details
Published in:Neurodegenerative disease management 2020-06, Vol.10 (3), p.543-558
Main Authors: Coneys, Rachel, Wood, Ian C
Format: Article
Language:English
Subjects:
acetylation
ageing
Alzheimer's
Alzheimer's disease
chromatin
Dementia
DNA methylation
Epigenetics
histone
Kinases
methylation
ncRNA
Pathology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Alzheimer’s disease is a progressive and fatal neurodegenerative disease affecting 50 million people worldwide, characterized by memory loss and neuronal degeneration. Current treatments have limited efficacy and there is no cure. Alzheimer's is likely caused by a combination of factors, providing several potential therapeutic targets. One area of interest is the epigenetic regulation of gene expression within the brain. Epigenetic marks, including DNA methylation and histone modifications, show consistent changes with age and in those with Alzheimer’s. Some epigenetic regulation has been linked to disease pathology and progression and are the focus of current research. Epigenetic regulators might make promising therapeutic targets yet challenges need to be overcome to generate an efficacious drug lacking deleterious side effects.
ISSN:1758-2024
1758-2032
DOI:10.2217/nmt-2019-0034